Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’

CEO Talat Imran: ‘I Think We Get An Inbound Partner Interest Every Week At This Point’

Executive Summary

In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.

You may also be interested in...



Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar

California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.

Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO

Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel